Nektar Inks $1.85B Bristol-Myers Cancer Drug Collaboration
According to the joint announcement, Bristol-Myers Squibb Co. has agreed to pay Nektar $1 billion in cash and buy $850 million worth of Nektar shares at $102.60 a piece. Nektar could also pocket roughly $1.78 billion in development, regulatory and sales milestones, the announcement added.
The companies said they will split global profits for the therapy,...
To view the full article, register now.